MAPT and Alzheimer disease: Levels of CSF Aβ42 were significantly reduced while levels of tau and ptau were significantly increased in AD samples compared to the age-matched controls when measured using INNO-BIA AlzBio3 (Figure S7; Table 3), consistent with expectations for a typical AD vs control sample set.